LB Pharmaceuticals, Inc. (LBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$38.09-6.76%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LBRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -36.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
LBRX — CFO transition
Dated 2026-09-03
CFO — Joseph M. Miller: The filing announces the appointment of an external candidate as CFO, which is a new hire rather than a departure of a sitting executive.
Why it matters: A timely meeting would show that the company is moving toward an FDA filing. A delay could push back that path.
Supportive ifLB Pharmaceuticals reports a pre-NDA meeting with the FDA in H2 2027, after the NOVA-2 results.
Worry ifThe company reports that the meeting is delayed beyond 2027 or is not planned after the trial results.
Why it matters: Starting this trial would advance a third use for LB-102. A missed start could slow the company's expansion plans.
Supportive ifThe company reports that its Phase 2 trial of LB-102 in add-on MDD has started by March 31, 2027.
Worry ifThe company reports that the trial has not started by March 31, 2027, or delays its start beyond early 2027.
Why it matters: This Phase 3 result is the main test of LB-102 in schizophrenia. Strong results could support the planned FDA review path.
Watch forTopline data arrive by June 30, 2027, and the trial meets its main goal with a clear benefit over placebo.
Also watch forThe trial misses its main goal, shows no clear benefit over placebo, or the readout slips beyond June 2027.
Why it matters: The company is loss-making and reports rising trial costs. A shorter runway could put pressure on its clinical plans.
Worry ifA later company update still says cash will fund planned operations beyond Q2 2029.
Less concerning ifA company update moves the runway to Q2 2029 or earlier, or reports new funding needed before then.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$168 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $585 loss on $10,000 · 5.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,129 loss on $10,000 · 31.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.